HMPL-306 (ranosidenib)
NCT07912398
Hutchmed · Phase 3 · Not yet recruiting · Enrollment 210
| Arm | Reported safety |
|---|---|
| HMPL-306 250 mg QD | n/r |
A count stays a count. This page does not turn a count into a percent.
Disease Pipeline Tools IDH-mutant glioma
IDH-mutant glioma
Programs, trials, and reported response and survival for IDH-mutant glioma.
HMPL-306 (ranosidenib)
Hutchmed · Phase 3 · Not yet recruiting · Enrollment 210
| Arm | Reported safety |
|---|---|
| HMPL-306 250 mg QD | n/r |
A count stays a count. This page does not turn a count into a percent.